Fairfield, Bush & Co. Sutro Biopharma, Inc. Call Options Transaction History
Fairfield, Bush & Co.
- $170 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding STRO
# of Institutions
132Shares Held
63.1MCall Options Held
205KPut Options Held
28.1K-
Suvretta Capital Management, LLC New York, NY7.46MShares$13 Million0.57% of portfolio
-
Black Rock Inc. New York, NY6.91MShares$12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$7.32 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.64MShares$6.34 Million0.42% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3MShares$5.22 Million0.03% of portfolio
About SUTRO BIOPHARMA, INC.
- Ticker STRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,161,500
- Market Cap $90.8M
- Description
- Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...